{"entity":{"id":"ash-alizadeh","kind":"person","name":"Ash A. Alizadeh","aka":[],"tldr":"Co-invented the CAPP-Seq method for reading tumour DNA in blood and used it to track lymphoma and lung cancer.","summary":"Ash Alizadeh is Professor of Medicine (Oncology) at Stanford University, within the Stanford Cancer Institute. An oncologist and computational biologist, he co-developed CAPP-Seq and phased variant enrichment for ultrasensitive circulating tumour DNA detection, applied to minimal residual disease in lymphoma and lung cancer, and led early work on tumour cell-of-origin classification in diffuse large B-cell lymphoma. His papers include a Nature Medicine report of an ultrasensitive method for quantitating circulating tumour DNA with broad patient coverage and the Nature paper identifying distinct types of diffuse large B-cell lymphoma by gene expression profiling. He continues to work on liquid biopsy and molecular residual disease testing.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Ash_Alizadeh","links":[{"label":"Stanford profile","url":"https://profiles.stanford.edu/search?q=Ash%20A.%20Alizadeh"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Alizadeh%20AA%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Ash%20A.%20Alizadeh"}],"tags":[],"related":[],"cancers":["dlbcl","nsclc"],"sections":[],"technologies":["liquid-biopsy","mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["stanford"],"pathways":[],"terms":["ctdna","mrd"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine (Oncology), Stanford University","institutionId":"stanford","specialisms":["Circulating tumour DNA","Lymphoma","Computational oncology"],"profiles":[{"label":"Stanford profile","url":"https://profiles.stanford.edu/search?q=Ash%20A.%20Alizadeh"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Alizadeh%20AA%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Ash%20A.%20Alizadeh"}],"papers":[{"title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","journal":"Nature Medicine","year":2014,"url":"https://doi.org/10.1038/nm.3519","doi":"10.1038/nm.3519"},{"title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","journal":"Nature","year":2000,"url":"https://doi.org/10.1038/35000501","doi":"10.1038/35000501"}],"orcid":"0000-0002-5153-5625"},"route":"/people/ash-alizadeh/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"institution":[{"id":"stanford","kind":"institution","name":"Stanford Health Care / Stanford Cancer Institute","route":"/institutions/stanford/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"}],"paper":[{"id":"paper-scherer-ctdna-lymphoma-subtypes-genome-evolution-sci-transl-med-2016","kind":"paper","name":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumour DNA","route":"/key-papers/paper-scherer-ctdna-lymphoma-subtypes-genome-evolution-sci-transl-med-2016/"}],"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}]}}